

08 August 2023



GODREJ CONSUMER PRODUCTS

Consumer Staples

Strong volume-led growth with margin expansion

- Volume-led growth continues in India business at 12% YoY in Q1; margin expansion seen across geographies
- Household insecticides delivered strong double-digit growth; personal care business muted
- Emphasis on volume-led category development to drive profitable growth; maintain BUY, TP Rs 1,159

Sustained volume-led growth: GCPL reported consolidated Q1FY24 revenue of Rs 34.5bn (+10% YoY, +15% CC), with volumes up 10% YoY. India business grew 9% YoY led by 12% volume growth, in line with the company's strategy of volumedriven category development. Value growth was lower than volume growth as GCPL passed on the benefits of lower input cost to consumers.

International markets robust: Revenue from Africa, the US, and the Middle East region (GUAM) was up 9% YoY (16% CC) due to healthy double-digit growth in FMCG category, and Latin America and SAARC grew 18% YoY (79% CC). Indonesia business registered strong revenue growth of 20% YoY in rupee terms (+15% CC) backed by structural initiatives taken last year.

Growth across categories: GCPL registered 14% YoY growth in the home care segment driven by double-digit volume and value growth in the household insecticides (HI) segment. Air fresheners also fared well. In insect repellants, GCPL continues to scale up distribution of access packs of *Goodknight* mini liquid vaporizer and *Hit* no-gas spray. Personal care grew 2% YoY alongside healthy volumes. *Magic* handwash delivered double-digit volume growth, whereas hair colour was muted off a high base.

Margin recovery continues: The company reported a 53.7% gross margin (+710bps YoY, +80bps QoQ). EBITDA margin expanded 190bps YoY (-140bps QoQ) to 18.6% despite a 79% YoY rise in working media investment. EBITDA margin for Indonesia business stood at 21.5% YoY (+420bps YoY), whereas GUAM was at 11.8% (+350bps).

Maintain BUY: GCPL reported strong volume growth across categories in the domestic market and saw improvement in the quality of profits. We expect the company's emphasis on category development, brand investment, market penetration and product launches to support profitable growth. The stock is trading at 48.9x/40x FY24E/FY25E EPS. We maintain BUY and continue to value the stock at a P/E multiple of 45x on FY25E EPS – in line with the long-term mean – for an unchanged TP of Rs 1,159.

Vikrant Kashyap

research@bobcaps.in

Key changes

	Target	Rating	
	<►	<►	
Ticker/P	rice	GCPL IN/Rs 1,009	
Market of	cap	US\$ 12.6bn	
Free floa	at	37%	
3M ADV	1	US\$ 12.8mn	
52wk hię	gh/low	Rs 1,102/Rs 794	
Promote	er/FPI/DII	63%/24%/13%	

Source: NSE | Price as of 8 Aug 2023

Key financials

FY23P	FY24E	FY25E
1,33,160	1,53,493	1,72,797
24,304	29,652	36,905
17,566	21,527	26,323
17.2	21.1	25.8
17.2	21.6	24.7
12.3	13.5	14.2
58.7	47.9	39.2
42.4	34.8	28.0
(4.5)	26.4	22.3
	1,33,160 24,304 17,566 17.2 17.2 12.3 58.7 42.4	1,33,160 1,53,493 24,304 29,652 17,566 21,527 17.2 21.1 17.2 21.6 12.3 13.5 58.7 47.9 42.4 34.8

Source: Company, Bloomberg, BOBCAPS Research | P - Provisional

Stock performance



Source: NSE








Fig 1 – Quarterly performance

(Rs mn)	Q1FY24	Q4FY23	Q1FY23	QoQ (%)	YoY (%)	Estimates	Variance (%)
Revenue	34,489	32,002	31,250	7.8	10.4	34,980	(1.4)
EBITDA	6,428	6,409	5,208	0.3	23.4	6,891	(6.7)
Adj. PAT	4,006	4,743	3,470	(15.5)	15.5	4,507	(11.1)
Gross Margin (%)	53.7	52.9	46.6	80bps	710bps	52.2	150bps
EBITDA Margin (%)	18.6	20.0	16.7	(140bps)	190bps	19.7	(110bps)
Adj. PAT Margin (%)	11.6	14.8	11.1	(320bps)	50bps	12.9	(130bps)

Source: Company, BOBCAPS Research

Fig 2 – Revenue and growth



Source: Company, BOBCAPS Research






Fig 4 – Revenue by geography

Source: Company, BOBCAPS Research





Source: Company, BOBCAPS Research

Fig 3 – EBITDA and margin






Fig 5 – Revenue share by geography



Source: Company, BOBCAPS Research

Fig 7 – Category growth YoY – Personal care



Source: Company, BOBCAPS Research



Earnings call highlights

- At a consolidated level, GCPL posted constant currency (CC) revenue growth of 15% YoY during Q1FY24, with inorganic underlying volume growth (UVG) of 10%.
 EBITDA for the quarter was up 28% YoY and PAT without exceptionals grew 19%.
 Operating cash flow expanded 4.9x YoY, albeit on a weak base, aided by significant working capital reduction across the board.
- In terms of YoY organic growth, UVG was up 8%, CC sales 13%, INR sales 9% and EBITDA 36%.
- Underlying sales growth (USG) was impacted by price deflation in soaps and a currency translation impact in Nigeria. PAT was behind EBITDA due to higher forex losses and MAT credit utilisation.
- Indonesia had a strong quarter despite another round of down stocking in modern trade. Volumes grew 12% YoY (15% CC) and EBITDA increased 53% YoY during Q1. Stocks in modern trade are down from a peak of 95 days to ~58 days. This along with a generally strong macro climate augurs well for the future of the business.
- GUAM also had a good quarter with 3% YoY (16% CC) volume growth and 55% YoY growth in EBITDA. The performance has been marginally impacted by devaluation of currency in Nigeria, which will optically have a significant impact over the next few quarters. The company expects to pass on the impact of currency devaluation to consumers with a lag.
- GCPL's partnership with the national distribution network in Nigeria is progressing well, and the company expects to see the benefits of the initiative as the year progresses.
- Management remains committed to its strategy of category development, simplification, and sustainability. On the category development front, the company has been consistently investing in brands, with media investments in India increasing by 125% YoY.
- During Q1, GCPL launched an innovative membrane-based air freshener called aer in the car segment.
- The company recently pilot-launched *Magic* floor cleaner an environment-friendly powder-to-liquid-based format catering to the large, fast-growing floor cleaning space.
- Shampoo hair colour is a fast-growing segment within the hair colour market. The company launched a Rs 15 shampoo hair colour in the south of India that has been doing well.
- HI performance has been driven by two factors: one, a relatively weaker summer and therefore an extended season and two, market development.
- The *Raymond* consumer care business reported muted sales of Rs 450mn in Q1 on account of 1.5 months of operation, down stocking and returns. However, the company is confident of growing the business.
- GCPL plans to invest ~Rs 9bn in organic manufacturing capex in India over the next 18 to 36 months, largely for volume growth and for logistics reasons. The



company intends to set up new manufacturing units in Tamil Nadu and Madhya Pradesh, and plans to add ~20% capacity in home and personal care funded by internal accruals and debt.

Valuation methodology

GCPL continues to display double-digit growth in the domestic market, backed by strong sale volumes across categories, alongside improvement in the quality of profits. Indonesia business maintained healthy growth momentum during Q1FY24 with margin expansion. GUAM too reported an upbeat quarterly performance backed by the FMCG segment.

We expect the company's emphasis on category development in India and simplification of international business together with brand investment, focused market penetration and product launches to spur profitable growth.

The stock is trading at 48.9x/40x FY24E/FY25E EPS. We maintain BUY and continue to value GCPL at a P/E multiple of 45x on FY25E EPS – in line with the long-term mean – for an unchanged TP of Rs 1,159.

Key risks

Key downside risks to our estimates are:

- continued headwinds in international markets, and
- relatively lower growth in household insecticides in India.

Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Britannia Industries	BRIT IN	13.5	4,605	5,844	BUY
Dabur India	DABUR IN	12.1	562	669	BUY
Godrej Consumer Products	GCPL IN	12.6	1,009	1,159	BUY
Hindustan Unilever	HUVR IN	73.4	2,566	3,069	BUY
ITC	ITC IN	68.4	452	523	BUY
Marico	MRCO IN	9.1	577	646	BUY
Nestle India	NEST IN	26.1	22,229	26,430	BUY
Tata Consumer Products	TATACONS IN	9.6	847	994	BUY
Zydus Wellness	ZYWL IN	1.2	1,516	1,556	HOLD

Source: BOBCAPS Research, NSE | Price as of 8 Aug 2023



Financials

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Total revenue	1,10,286	1,22,765	1,33,160	1,53,493	1,72,797
EBITDA	23,883	23,951	24,304	29,652	36,905
Depreciation	2,039	2,099	2,363	2,623	3,025
EBIT	21,844	21,852	21,941	27,029	33,880
Net interest inc./(exp.)	(1,266)	(1,102)	(1,757)	(1,216)	(834)
Other inc./(exp.)	671	897	1,685	1,785	2,051
Exceptional items	445	98	541	0	0
EBT	20,804	21,553	21,327	27,598	35,098
Income taxes	3,595	3,719	4,303	6,072	8,774
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	17,208	17,834	17,025	21,527	26,323
Adjustments	445	98	541	0	0
Adjusted net profit	17,653	17,931	17,566	21,527	26.323

Balance Sheet					
Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Accounts payables	20,124	21,630	18,232	18,641	18,670
Other current liabilities	2,262	2,238	2,290	2,640	2,972
Provisions	1,871	1,832	1,786	2,058	2,317
Debt funds	17,965	16,399	10,720	8,040	4,824
Other liabilities	6,217	3,681	4,018	4,534	4,941
Equity capital	1,023	1,023	1,023	1,023	1,023
Reserves & surplus	93,367	1,14,537	1,36,920	1,58,446	1,84,770
Shareholders' fund	94,389	1,15,559	1,37,942	1,59,469	1,85,792
Total liab. and equities	1,42,828	1,61,340	1,74,988	1,95,382	2,19,517
Cash and cash eq.	6,722	11,078	3,907	10,293	18,519
Accounts receivables	10,045	11,163	12,453	14,354	16,160
Inventories	17,163	21,299	15,372	19,857	25,040
Other current assets	4,223	4,890	4,432	5,108	5,751
Investments	6,791	10,154	30,290	34,669	39,924
Net fixed assets	12,102	12,749	14,374	16,554	19,146
CWIP	530	1,148	416	416	416
Intangible assets	76,034	78,459	83,996	84,382	84,812
Deferred tax assets, net	6,768	7,315	7,028	7,028	7,028
Other assets	2,451	3,086	2,721	2,721	2,721
Total assets	1,42,828	1,61,341	1,74,988	1,95,382	2,19,517

Cash Flows

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Cash flow from operations	20,296	14,506	21,506	17,391	20,970
Capital expenditures	(1,639)	(2,765)	(2,274)	(5,189)	(6,048)
Change in investments	(108)	(4,096)	(16,629)	(4,379)	(5,256)
Other investing cash flows	(1,409)	(1,781)	1,320	1,785	2,051
Cash flow from investing	(3,155)	(8,642)	(17,583)	(7,783)	(9,253)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	(13,720)	(2,198)	(6,344)	0	0
Interest expenses	(1,589)	(1,123)	(1,116)	(1,216)	(834)
Dividends paid	0	0	0	0	0
Other financing cash flows	(2,853)	(474)	(483)	(2,006)	(2,658)
Cash flow from financing	(18,162)	(3,795)	(7,943)	(3,222)	(3,492)
Chg in cash & cash eq.	(1,021)	2,068	(4,020)	6,386	8,225
Closing cash & cash eq.	5,241	7,509	3,576	9,962	18,188

Per Share					
Y/E 31 Mar (Rs)	FY21A	FY22A	FY23P	FY24E	FY25E
Reported EPS	16.8	17.4	16.7	21.1	25.8
Adjusted EPS	17.3	17.5	17.2	21.1	25.8
Dividend per share	0.0	0.0	0.0	0.0	0.0
Book value per share	92.3	113.1	135.0	156.0	181.8
Valuations Ratios					
Y/E 31 Mar (x)	FY21A	FY22A	FY23P	FY24E	FY25E
EV/Sales	9.4	8.4	7.7	6.7	6.0
EV/EBITDA	43.2	43.1	42.4	34.8	28.0
Adjusted P/E	58.5	57.5	58.7	47.9	39.
P/BV	10.9	8.9	7.5	6.5	5.
DuPont Analysis					
Y/E 31 Mar (%)	FY21A	FY22A	FY23P	FY24E	FY25
Tax burden (Net profit/PBT)	82.7	82.7	79.8	78.0	75.
Interest burden (PBT/EBIT)	95.2	98.6	97.2	102.1	103.
EBIT margin (EBIT/Revenue)	19.8	17.8	16.5	17.6	19.
Asset turnover (Rev./Avg TA)	77.2	76.1	76.1	78.6	78.
Leverage (Avg TA/Avg Equity)	1.5	1.4	1.3	1.2	1.
Adjusted ROAE	18.2	15.4	12.3	13.5	14.
Ratio Analysis Y/E 31 Mar	FY21A	FY22A	FY23P	FY24E	FY25
YoY growth (%)					
· J · · (··/					
Revenue	11.3	11.3	8.5	15.3	12.
Revenue EBITDA	11.3 11.4	11.3 0.3	8.5 1.5	15.3 22.0	
EBITDA			1.5		24.
EBITDA Adjusted EPS	11.4	0.3	••••	22.0	24.
EBITDA Adjusted EPS Profitability & Return ratios (%)	11.4	0.3	1.5	22.0	24. 22.
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin	11.4 9.6 21.7	0.3 3.6 19.5	1.5 (4.5)	22.0 26.4 19.3	24. 22. 21.
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin	11.4 9.6	0.3 3.6	1.5 (4.5) 18.3	22.0 26.4	24. 22. 21. 19.
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin	11.4 9.6 21.7 19.8	0.3 3.6 19.5 17.8	1.5 (4.5) 18.3 16.5	22.0 26.4 19.3 17.6	24. 22. 21. 19. 15.
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin	11.4 9.6 21.7 19.8 16.0	0.3 3.6 19.5 17.8 14.6	1.5 (4.5) 18.3 16.5 13.2	22.0 26.4 19.3 17.6 14.0	24. 22. 21. 19. 15. 14.
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE	11.4 9.6 21.7 19.8 16.0 18.2	0.3 3.6 19.5 17.8 14.6 15.4	1.5 (4.5) 18.3 16.5 13.2 12.3	22.0 26.4 19.3 17.6 14.0 13.5	24. 22. 21. 19. 15. 14.
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE	11.4 9.6 21.7 19.8 16.0 18.2	0.3 3.6 19.5 17.8 14.6 15.4	1.5 (4.5) 18.3 16.5 13.2 12.3	22.0 26.4 19.3 17.6 14.0 13.5	24. 22. 21. 19. 15. 14.
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days)	11.4 9.6 21.7 19.8 16.0 18.2 21.5	0.3 3.6 19.5 17.8 14.6 15.4 18.0	1.5 (4.5) 18.3 16.5 13.2 12.3 15.4	22.0 26.4 19.3 17.6 14.0 13.5 16.5	24. 22. 21. 19. 15. 14. 17.
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables	11.4 9.6 21.7 19.8 16.0 18.2 21.5 33	0.3 3.6 19.5 17.8 14.6 15.4 18.0 33	1.5 (4.5) 18.3 16.5 13.2 12.3 15.4 34	22.0 26.4 19.3 17.6 14.0 13.5 16.5 34	24. 22. 21. 19. 15. 14. 17. 3 3 11
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory Payables	11.4 9.6 21.7 19.8 16.0 18.2 21.5 33 127	0.3 3.6 19.5 17.8 14.6 15.4 18.0 33 128	1.5 (4.5) 18.3 16.5 13.2 12.3 15.4 34 84	22.0 26.4 19.3 17.6 14.0 13.5 16.5 34 98	24. 22. 21. 19. 15. 14. 17. 3 3 11
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory	11.4 9.6 21.7 19.8 16.0 18.2 21.5 33 127	0.3 3.6 19.5 17.8 14.6 15.4 18.0 33 128	1.5 (4.5) 18.3 16.5 13.2 12.3 15.4 34 84	22.0 26.4 19.3 17.6 14.0 13.5 16.5 34 98	24. 22. 19. 15. 14. 17. 3 11. 8
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory Payables Ratios (x)	11.4 9.6 21.7 19.8 16.0 18.2 21.5 33 127 149	19.5 17.8 14.6 15.4 18.0 33 128 130	1.5 (4.5) 18.3 16.5 13.2 12.3 15.4 34 84 99	22.0 26.4 19.3 17.6 14.0 13.5 16.5 34 98 92	24. 22. 19. 15. 14. 17. 3 11. 8 0.
EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory Payables Ratios (x) Gross asset turnover	11.4 9.6 21.7 19.8 16.0 18.2 21.5 33 127 149 0.7	19.5 17.8 14.6 15.4 18.0 33 128 130 0.7	1.5 (4.5) 18.3 16.5 13.2 12.3 15.4 34 84 99 0.7	22.0 26.4 19.3 17.6 14.0 13.5 16.5 34 98 92 0.7	12.0 24.3 22.7 19.0 15.7 14.1 17.1 17.1 3.0 11.0 83 83 83 83 83 84 0.0 3.3 40.0

Source: Company, BOBCAPS Research | Note: TA = Total Assets



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited** Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051** SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025** Brand Name: **BOBCAPS** Trade Name: www.barodaetrade.com



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): GODREJ CONSUMER PRODUCTS (GCPL IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of Individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

GODREJ CONSUMER PRODUCTS



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.